AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$ICLR

Murphy Ronan Martin sold $876K of ICLR

Murphy Ronan Martin sold 5,005 shares of ICON PLC (ICLR) at $175.00 ($0.88M total) on 2026-09-17.

Original reporting
SEC EDGAR · Murphy Ronan Martin
Published Sep 18, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The director's sale represents a modest reduction in ownership, unlikely to move the stock significantly.

02

Market read

Small insider sale with limited market impact.

03

What to watch

Insider may have tax or personal liquidity reasons unrelated to company outlook.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑17

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

Director Murphy Ronan Martin sold 5,005 shares of ICON PLC for $875,875 on 2026-09-17.

Expected impact

Potential short-term downward pressure on ICLR share price.

Evidence & confidence

The sale size is modest relative to holdings and market cap; impact likely limited.

Market effects

Sector

Minimal effect on the healthcare services sector.

Regional

Limited to UK/US investors tracking ICON PLC.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Individual
    Murphy Ronan Martin

    Director of ICON PLC who sold shares.

  • Company
    ICON PLC

    Global provider of drug development services.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICLR insider trading history →

Related articles

JUL 29
$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

finanznachrichten.de3 min
JUL 29
$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

SEC EDGAR 6-K2 min
JUL 28
$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

investing.com3 min
JUL 28
$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.

rttnews.com2 min